Press Releases SK bioscience Co.,Ltd.

Equities

A302440

KR7302440003

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
59,600 ^KRW	+0.17%		-0.33%	-17.22%

May. 03	SK Bioscience's Attributable Loss Narrows in Q1	MT
Mar. 28	SK Bioscience Signs Deal with Sanofi for Five Vaccine Types	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Varicella Zoster Infections Pipeline Landscape Analysis of 03+ Companies by DelveInsight \| Leading Companies - Curevo Vaccine, GeneOne Life Science, SK Bioscience, and Others	22-10-04	AQ
SK bioscience : Material Business Matters Related to Investment Decisions (Approval of change of domestic product license for Novavax Corona 19 vaccine (addition of indications for adolescents aged 12 to 17))	22-08-18	PU
South Korea, Gates Foundation in deal to prepare for 'next pandemic'	22-08-16	AQ
SK bioscience : Material Business Matters Related to Investment Decisions (Investigational new drug (IND) application for phase III clinical trial of heterologous booster shot of GBP510 in Nepal)	22-08-09	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Application for EMA conditional marketing authorization (CMA) for COVID-19 vaccine, SKYCovion(GBP510))	22-08-02	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Application for UK conditional marketing authorization (CMA) for COVID-19 vaccine, SKYCovion(GBP510))	22-08-01	PU
SK bioscience : Interim Report on Business Performance (Fair Disclosure)	22-07-29	PU
SK bioscience : Conclusion of Single SalesContract or Supply Contract	22-07-20	PU
SK bioscience : Conclusion of Single SalesContract or Supply Contract	22-07-20	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Approval of Phase III clinical trial (IND) application on COVID-19 vaccine GBP510 in Thailand)	22-07-14	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Approval of the domestic product licensing for COVID-19 vaccine SKYCovione(GBP510))	22-06-29	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Booster-shot Phase III clinical trial (IND) application for COVID-19 vaccine GBP510 in Thailand)	22-05-24	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Application for the domestic product licensing for COVID-19 vaccine GBP510)	22-05-02	PU
SK bioscience : Interim Report on Business Performance (Fair Disclosure)	22-05-02	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Announcement of the key results of Phase III clinical of COVID-19 vaccine GBP510)	22-05-02	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Announcement of the key results of Phase III clinical of COVID-19 vaccine GBP510)	22-04-26	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Approval of Phase 3 Clinical Trial Plan (IND) on GBP510 booster shot, COVID-19 vaccine)	22-04-25	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Application for change of domestic product license for Novavax Corona 19 vaccine (addition of indications for adolescents aged 12 to 17))	22-04-11	PU
SK bioscience : Material Business Matters Related to Investment Decisions (Booster-shot Phase III clinical trial (IND) application for COVID-19 vaccine GBP510)	22-03-24	PU
SK bioscience : Conclusion of Single SalesContract or Supply Contract	22-03-22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SK bioscience Co.,Ltd.

Equities

A302440

KR7302440003

Press Releases

Filters